ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $107.3333.
Several research analysts have commented on the stock. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday.
ANI Pharmaceuticals Stock Performance
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last posted its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77. The firm had revenue of $237.46 million for the quarter, compared to the consensus estimate of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The business’s revenue was up 20.5% compared to the same quarter last year. During the same period last year, the firm posted $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, analysts predict that ANI Pharmaceuticals will post 7.73 earnings per share for the current fiscal year.
Insider Transactions at ANI Pharmaceuticals
In other news, insider Christopher Mutz sold 5,323 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $78.02, for a total value of $415,300.46. Following the transaction, the insider owned 84,840 shares in the company, valued at approximately $6,619,216.80. This trade represents a 5.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Patrick D. Walsh sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total transaction of $806,300.00. Following the completion of the transaction, the director owned 38,432 shares in the company, valued at $3,098,772.16. This represents a 20.65% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 100,564 shares of company stock valued at $7,800,862. 8.10% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Maryland State Retirement & Pension System boosted its holdings in ANI Pharmaceuticals by 5.4% in the fourth quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock valued at $206,000 after acquiring an additional 134 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in ANI Pharmaceuticals by 1.5% in the first quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock valued at $736,000 after acquiring an additional 143 shares in the last quarter. Illinois Municipal Retirement Fund boosted its holdings in ANI Pharmaceuticals by 1.7% in the third quarter. Illinois Municipal Retirement Fund now owns 8,538 shares of the specialty pharmaceutical company’s stock valued at $782,000 after acquiring an additional 145 shares in the last quarter. Amalgamated Bank boosted its holdings in ANI Pharmaceuticals by 3.1% in the third quarter. Amalgamated Bank now owns 5,066 shares of the specialty pharmaceutical company’s stock valued at $464,000 after acquiring an additional 154 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co boosted its holdings in ANI Pharmaceuticals by 1.0% in the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after acquiring an additional 198 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Read More
- Five stocks we like better than ANI Pharmaceuticals
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
